Vetoquinol Is Moving Forward With the Acquisition of Profender® And Drontal® And Related Pipeline Assets Following Communic...
09 Giugno 2020 - 6:34PM
Business Wire
Regulatory News:
The European Commission (EC) has approved, under the EU merger
Regulation, the proposed acquisition of Bayer’s Animal Health
Division by Elanco Animal Health. This EC decision is conditional
on the divestment of several products, including the
Profender® and Drontal® product families, as well as
the related pipeline assets, to be acquired by Vetoquinol
(Paris:VETO).
The approval of the European Commission marks an important
milestone for Vetoquinol towards the completion of the acquisition
and the integration of these product families into the Vetoquinol
product range.
On February 12th 2020, Vetoquinol had announced the acquisition
of the Profender® and Drontal® product families for
the European Economic Area and the UK. The Profender® and
Drontal® families of products are spot-on and tablet
de-wormers for cats and dogs.
The transaction is expected to close early August 2020 and
remains subject to additional regulatory approvals and customary
closing conditions.
Matthieu Frechin, CEO of Vetoquinol, said "We are extremely
pleased to share this major regulatory step towards the completion
of the acquisition of the Profender® and Drontal®
product lines. The acquisition of these two strong brands as well
as the related pipeline is at the core of Vetoquinol strategy. On
the one hand, they will significantly increase the size of our
business and our visibility in the parasiticide segment, one of our
strategic therapeutic areas. On the other hand, they will
strengthen our portfolio of Essentials, the engine of our
growth.”
Next update: 2020 first half Financial results - July
30th, 2020 after Market close
About Vetoquinol Vetoquinol is a leading global animal
health company that supplies drugs and non-medicinal products for
the livestock (cattle and pigs) and pet (dogs and cats) markets. As
an independent pure player, Vetoquinol designs, develops and sells
veterinary drugs and non-medicinal products in Europe, the Americas
and the Asia Pacific region. Since its foundation in 1933,
Vetoquinol has pursued a strategy combining innovation with
geographical diversification. The Group's hybrid growth is driven
by the reinforcement of its product portfolio coupled with
acquisitions in high potential growth markets. At April 30th 2020,
Vetoquinol employs 2,403 people. Vetoquinol has been listed on
Euronext Paris since 2006 (symbol: VETO).
For further information, go to: www.vetoquinol.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200609005678/en/
VETOQUINOL Investor
Relations Fanny Toillon Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com
KEIMA Communication Investor and
Media Relations Emmanuel Dovergne Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr
Grafico Azioni Vetoquinol (EU:VETO)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Vetoquinol (EU:VETO)
Storico
Da Apr 2023 a Apr 2024